Information Provided By: 
Fly News Breaks for April 25, 2016
VRX
Apr 25, 2016 | 12:56 EDT
JPMorgan analyst Chris Schott calls Joe Papa a "well-known and fairly non-controversial" CEO. As such, his hiring is a positive for Valeant Pharmaceuticals as it seeks to move past recent controversies, Schott tells investors in a research note. The analyst also views the appointment as an indication that Valeant is close to filing its annual report, which he views as the key near-term catalyst for the shares. Schott has an Overweight rating on Valeant. The stock is up 49c to $36.47 in midday trading.
News For VRX From the Last 2 Days
There are no results for your query VRX
